Augmentation de capital - achat de Fruitflow® II SD
Avant la publication, les informations contenues dans cette annonce ont été considérées par la Société comme constituant des informations privilégiées tel que stipulé en vertu de la réglementation britannique sur les abus de marché. Avec la publication de cette annonce, ces informations sont désormais considérées comme étant du domaine public.
28 Mars 2024
Provexis plc
("Provexis" ou la "Société")
Purchase of Fruitflow® II SD from dsm-firmenich and issue of equity
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce that it has agreed to purchase a further batch of Fruitflow II SD ('Fruitflow') inventory from dsm-firmenich, to satisfy increasing demand for Fruitflow.
The inventory purchase totals £341,000, and Provexis has agreed to issue 45,123,732 new ordinary shares of 0.1p each in the Company (the 'New Provexis Shares') to dsm-firmenich in part satisfaction of the inventory purchase, with the remainder of the inventory purchase to be paid for in cash.
The Company and dsm-firmenich agreed a valuation of £293,304 for the 45,123,732 New Provexis Shares, based on the 0.65 pence closing mid-market price per Ordinary Share on 15 March 2024.
The 45,123,732 New Provexis Shares were valued at £266,230 at the 0.59 pence closing mid-market price per Ordinary Share on 27 March 2024, being the latest practicable date prior to this announcement, and they represent 2.03% of the Company's existing issued share capital.
The Company is also pleased to confirm that it has now completed the setup of a new Irish subsidiary company, Provexis Ireland Limited, which will facilitate tariff free sales of Fruitflow to customers in the EU.
Provexis Ireland Limited will use an outsourced fulfilment centre in Ireland to serve EU customers for Fruitflow, and the majority of the inventory purchased from dsm-firmenich today will be shipped to the new fulfilment centre in Ireland.
Application has been made to the London Stock Exchange for the 45,123,732 New Provexis Shares to be admitted to trading on AIM. It is expected that admission will become effective and that trading in the New Provexis Shares will commence on or around 5 April 2024 ('Admission').
Following Admission, the Company's enlarged issued share capital will comprise 2,262,945,255 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 2,262,945,255 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
It has been agreed with dsm-firmenich that the 45,123,732 New Provexis Shares will be issued to DSM Venturing BV, a significant existing shareholder in Provexis. On 27 March 2024 the Company learned that DSM Venturing BV's current shareholding is 130,923,358 shares, being 5.90% of the Company's existing issued share capital, and after the issue of the 45,123,732 New Provexis Shares DSM Venturing BV will hold 176,047,090 shares, which will be 7.78% of the Company's enlarged issued share capital.
Ian Ford, CEO of Provexis, commented:
'We are delighted to have completed this further purchase of Fruitflow inventory from dsm-firmenich with the majority of the consideration payable in new Provexis shares, and we would like to thank dsm-firmenich pour leur soutien continu.
Provexis and dsm-firmenich have acted in commercial partnership for Fruitflow since 2010, and the Company was delighted to have agreed a new long-term partnership with dsm-firmenich in 2022 based on the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO (trimethylamine-n-oxide).
The gut microbiome partnership has continued to progress well, and there has been some encouraging and ongoing interest in this technology from some significant global customers.
The further purchase of Fruitflow inventory announced today has been made to satisfy an increasing demand from customers of Provexis for the product and reflects the positive momentum that Provexis has enjoyed since initiating the process to transfer customers from dsm-firmenich to the Company in January 2023. The Company is also pleased to have completed the setup of a new Irish subsidiary company and related fulfilment centre, which will greatly facilitate tariff free sales of Fruitflow to customers in the EU.'
Pour de plus amples informations s'il vous plaît contacter:
Provexis plc Ian Ford, PDG Dawson Buck, président
| Tél: 07490 391888 |
Allenby Capital Limitée Nick Naylor / Liz Kirchner / Lauren Wright | Tel: 020 3328 5656
|
Notes aux rédacteurs
À propos de Provexis plc
Provexis, cité par AIM, se concentre sur le développement, l'octroi de licences et la vente de son ingrédient alimentaire fonctionnel exclusif et scientifiquement prouvé Fruitflow® pour la santé cardiaque.
Fruitflow est un ingrédient naturel révolutionnaire qui aide à l'agrégation plaquettaire. Cela aide à favoriser un flux sanguin et une circulation normaux, ce qui à son tour profite à la santé cardiovasculaire. Fruitflow aide les plaquettes à circuler librement et en douceur dans votre sang, sans coller les unes aux autres ou aux vaisseaux sanguins eux-mêmes. Le sang qui coule librement aide à réduire le stress sur votre système cardiovasculaire.
Fruitflow est une forme hautement concentrée de bioactifs qui ne contient pas de lycopène et contient plus de 30 composés antiplaquettaires connus. Des études cliniques publiées ont montré que Fruitflow agit pour maintenir un flux sanguin sain de la même manière que l'aspirine à 75 mg, mais avec une action plus douce et réversible ; Fruitflow a un effet antiplaquettaire similaire à une dose unique d'aspirine - mais lorsqu'il est pris quotidiennement, il n'a aucun des effets secondaires de l'aspirine.
La science derrière Fruitflow a été validée par les principales publications d'examen par les pairs et les autorités réglementaires. Fruitflow est le seul antiplaquettaire naturel à avoir une allégation de santé approuvée par l'Autorité européenne de sécurité des aliments, indiquant que 150 mg de Fruitflow "aident à maintenir une agrégation plaquettaire normale, ce qui contribue à une circulation sanguine saine".
Fruitflow présente un certain nombre d'avantages spécifiques pour la santé qui ont été reflétés dans des dépôts de brevets distincts pour l'utilisation de Fruitflow dans :
· atténuer l'inflammation induite par l'exercice ;
· gérer la tension artérielle;
· protéger contre les effets néfastes de la pollution de l’air sur le système cardiovasculaire du corps. Des travaux en laboratoire ont montré que Fruitflow peut réduire d'environ un tiers l'activation plaquettaire provoquée par les particules en suspension dans l'air, telles que celles provenant des émissions de diesel ; et
· conferring health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO, following the completion of a successful human study which is further detailed here www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html.
Provexis sells a high quality dietary supplement product containing Fruitflow and Omega-3 from its website www.fruitflowplus.com on a mail order basis. The product is also available to purchase from Amazon.co.uk and from Holland & Barrett.
Provexis has been working with BYHEALTH, a circa £3bn listed Chinese dietary supplement business, for more than seven years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in China are typically required to obtain the necessary regulatory clearances in China, and a significant investment in eight separate Fruitflow studies has been undertaken at BYHEALTH's expense. Completed studies have shown excellent results in use for Fruitflow, and they provide strong evidence for the efficacy of Fruitflow on platelet function.
Le système de réglementation chinois pour les ingrédients d'aliments de santé fonctionnels, tels que Fruitflow, est régi par l'Administration d'État pour la régulation du marché (la « SAMR ») et est basé sur une liste définie d'allégations fonctionnelles de santé autorisées que les propriétaires de marques sont autorisés à utiliser sur les étiquettes des produits.
In August 2023 the Company was delighted to report that BYHEALTH had submitted: i) the first application for a new permitted health function claim and ii) some related product registration applications.
The significance of these major developments for Fruitflow in China is further outlined here www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods#. BYHEALTH has noted that it has been working on the project since 2015, with 'tens of millions of funds' (RMB) invested by BYHEALTH in the research and development work.
Provexis a été fondée en 1999 et son siège social est situé à Reading, dans le Berkshire. Les actions de Provexis sont négociées sur le marché AIM de la Bourse de Londres sous le symbole PXS.
For further information, please visit www.provexis.com and www.fruitflowplus.com.
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.